What additional work‑up is indicated for a patient whose platelet count increased from 540 × 10⁹/L to 707 × 10⁹/L while the complete blood count, peripheral smear, comprehensive metabolic panel, and thyroid‑stimulating hormone level are otherwise normal?

Work-Up for Progressive Thrombocytosis (540→707 × 10⁹/L)

You need to rule out essential thrombocythemia (ET) or another myeloproliferative neoplasm (MPN) by testing for JAK2 V600E mutation, and if negative, proceed with calreticulin (CALR) and MPL gene mutations, followed by bone marrow biopsy if mutations are positive or clinical suspicion remains high.

Algorithmic Approach to This Rising Platelet Count

Step 1: Confirm Persistent Thrombocytosis

• Repeat CBC in 2-4 weeks to document sustained elevation ≥450 × 10⁹/L 1
• Your patient already shows progression (540→707), suggesting this is not transient

Step 2: Exclude Secondary (Reactive) Causes

While you've already checked TSH (normal), you need to systematically exclude other common reactive causes:

Essential additional testing:

• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) - to detect occult infection, inflammation, or malignancy 2, 3
• Iron studies with ferritin - iron deficiency is a frequent cause of reactive thrombocytosis 1, 3
• Chest imaging if not recently done - to exclude occult malignancy or infection 2

Key clinical context to document:

• Recent surgery, trauma, or tissue damage (causes 42% of secondary thrombocytosis) 2
• Active infection (24% of cases) 2
• Known malignancy (13% of cases) 2
• Chronic inflammatory conditions (10% of cases) 2
• Prior splenectomy 1

Step 3: Assess for Primary Thrombocytosis (MPN)

Critical distinguishing features favoring primary over secondary thrombocytosis:

The research evidence shows that primary thrombocytosis typically presents with 2, 4:

• Higher absolute platelet counts (though overlap exists)
• Arterial and venous thrombotic complications (56% in MPD vs 4% in reactive) 4
• Bleeding symptoms or vasomotor symptoms (headaches, erythromelalgia, visual disturbances)
• Splenomegaly on examination

Laboratory clues suggesting primary disease:

• Elevated hematocrit or hemoglobin (suggests polycythemia vera)
• Elevated white blood cell count
• Elevated lactate dehydrogenase (LDH)
• Elevated serum potassium 2

Step 4: Molecular Testing (Essential)

If no clear secondary cause is identified, proceed immediately with:

1. JAK2 V600E mutation testing - present in ~50-60% of ET cases 1, 3
2. If JAK2 negative: Test for CALR and MPL mutations 1, 3
3. Bone marrow biopsy with histology - required for definitive diagnosis 1, 3

The 2007 WHO criteria (revised) for ET require 1:

• Sustained platelet count ≥450 × 10⁹/L
• Bone marrow showing megakaryocytic proliferation with enlarged, mature megakaryocytes
• Not meeting criteria for PV, PMF, CML, or MDS
• Demonstration of JAK2 V600E or other clonal marker, OR absence of reactive causes

Step 5: Peripheral Blood Smear Review

Request hematopathology review specifically looking for:

• Megakaryocyte fragments
• Abnormal platelet morphology
• Left-shifted myeloid cells (suggests CML)
• Dysplastic features (suggests MDS)
• Nucleated red blood cells or teardrop cells (suggests myelofibrosis)

Critical Pitfalls to Avoid

1. Don't assume it's reactive just because one test is normal - 82% of extreme thrombocytosis (>1000 × 10⁹/L) is reactive 4, but your patient's progressive rise warrants full MPN work-up

2. Don't delay molecular testing - if CRP, ferritin, and clinical assessment don't reveal an obvious reactive cause, proceed directly to JAK2 testing rather than prolonged observation 3

3. Don't rely solely on platelet count magnitude - while primary thrombocytosis tends to have higher counts, significant overlap exists 2

4. Don't forget platelet function testing - if MPN is suspected, abnormal platelet aggregation studies support the diagnosis (abnormal in most ET patients, normal in most reactive cases) 5

Thrombotic Risk Assessment

If ET is diagnosed, calculate the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia to guide aspirin and cytoreductive therapy decisions 3. Risk factors include:

• Age >60 years
• Prior thrombosis
• JAK2 V600E mutation
• Cardiovascular risk factors

Bottom line: Your patient needs JAK2 mutation testing now, along with CRP and iron studies. If JAK2 is positive or clinical suspicion remains high despite negative JAK2, proceed to bone marrow biopsy. The progressive rise from 540 to 707 × 10⁹/L with otherwise normal labs makes this a mandatory work-up to exclude a potentially serious clonal disorder.